Laser-based treatments have emerged in the past 15 years as an alternative to transurethral resection of the prostate (TURP) for treatment of symptomatic benign prostatic hyperplasia. Increasing demand for a…
The high-powered holmium laser is an excellent tool for the surgical treatment of benign prostatic hyperplasia. This article discusses the background of holmium use in the prostate and describes the…
Transurethral resection of the prostate (TURP) is the historical gold standard therapy for lower urinary tract symptoms secondary to obstruction from benign prostatic hyperplasia (BPH). Over the last 15 years, medical…
Benign prostatic hyperplasia is characterized by smooth muscle and epithelial proliferation primarily within the prostatic transition zone that can cause a variety of problems for a patient, the most frequent…
The role of urodynamics in the evaluation of lower urinary tract symptoms in men with benign prostatic hyperplasia is controversial despite the additional information regarding bladder function and outlet obstruction…
The approach to a patient with benign prostatic hyperplasia and lower urinary tract symptoms (LUTS) begins with a detailed history. The goal is to clearly identify the patient’s urinary complaints,…
Historically, benign prostatic hyperplasia (BPH) has been a major focus of urologic practice and surgery. But a simplistic causal relationship among prostatic enlargement, progressive obstruction, lower urinary tract symptoms, retention,…
Robotic-assisted laparoscopic radical prostatectomy (RALP) has been rapidly adopted in the last few years despite having a prolonged learning curve. This article describes the RALP learning curve, reviews in detail…
The prevalence of prostate cancer (PCa) is high and increases with age. PCa is the most common cutaneous cancer in American men. Prostate-specific antigen (PSA) screening has impacted the detection…
This article reviews the concepts and rationale behind targeted agents that are currently in clinical testing for patients with castration resistant prostate cancer (CRPC). Advances in our understanding of the…
